Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan

T. C. Lin, C. Y. Yang, Y. H. Kao Yang, S. J. Lin

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

A pharmacoepidemiology study was conducted using the health insurance database in Taiwan to assess compliance with osteoporosis drug regimens and the impact of compliance on the risk for secondary fractures. Patients 50 years of age with vertebral/hip fracture who had been started on alendronate therapy for the first time only after the fracture were included. Compliance was measured using the medication possession ratio (MPR) and was included as a time-dependent covariate in the Cox model to compare the difference between compliant (MPR 80%) and noncompliant patients (MPR 80%) with respect to risk for subsequent hip fractures. Only 38% of the study population remained compliant during the first year of treatment. Over the 4-year follow-up period, the risk of hip fracture among the compliant patients was 70% lower than that among the noncompliant ones (adjusted hazard ratio (HR) 0.30). Among patients with osteoporosis in Taiwan who had experienced a fracture and had started alendronate therapy, compliance with the dosage regimen was suboptimal. It was also found that compliance significantly reduced the risk of secondary hip fracture up to 4 years.

Original languageEnglish
Pages (from-to)109-116
Number of pages8
JournalClinical Pharmacology and Therapeutics
Volume90
Issue number1
DOIs
Publication statusPublished - 2011 Jul 1

Fingerprint

Alendronate
Hip Fractures
Taiwan
Osteoporosis
Compliance
Pharmacoepidemiology
Health Insurance
Proportional Hazards Models
Therapeutics
Databases
Pharmaceutical Preparations
Population

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{60d5ab0bc331413781b02e6702490f15,
title = "Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan",
abstract = "A pharmacoepidemiology study was conducted using the health insurance database in Taiwan to assess compliance with osteoporosis drug regimens and the impact of compliance on the risk for secondary fractures. Patients 50 years of age with vertebral/hip fracture who had been started on alendronate therapy for the first time only after the fracture were included. Compliance was measured using the medication possession ratio (MPR) and was included as a time-dependent covariate in the Cox model to compare the difference between compliant (MPR 80{\%}) and noncompliant patients (MPR 80{\%}) with respect to risk for subsequent hip fractures. Only 38{\%} of the study population remained compliant during the first year of treatment. Over the 4-year follow-up period, the risk of hip fracture among the compliant patients was 70{\%} lower than that among the noncompliant ones (adjusted hazard ratio (HR) 0.30). Among patients with osteoporosis in Taiwan who had experienced a fracture and had started alendronate therapy, compliance with the dosage regimen was suboptimal. It was also found that compliance significantly reduced the risk of secondary hip fracture up to 4 years.",
author = "Lin, {T. C.} and Yang, {C. Y.} and {Kao Yang}, {Y. H.} and Lin, {S. J.}",
year = "2011",
month = "7",
day = "1",
doi = "10.1038/clpt.2011.62",
language = "English",
volume = "90",
pages = "109--116",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan. / Lin, T. C.; Yang, C. Y.; Kao Yang, Y. H.; Lin, S. J.

In: Clinical Pharmacology and Therapeutics, Vol. 90, No. 1, 01.07.2011, p. 109-116.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan

AU - Lin, T. C.

AU - Yang, C. Y.

AU - Kao Yang, Y. H.

AU - Lin, S. J.

PY - 2011/7/1

Y1 - 2011/7/1

N2 - A pharmacoepidemiology study was conducted using the health insurance database in Taiwan to assess compliance with osteoporosis drug regimens and the impact of compliance on the risk for secondary fractures. Patients 50 years of age with vertebral/hip fracture who had been started on alendronate therapy for the first time only after the fracture were included. Compliance was measured using the medication possession ratio (MPR) and was included as a time-dependent covariate in the Cox model to compare the difference between compliant (MPR 80%) and noncompliant patients (MPR 80%) with respect to risk for subsequent hip fractures. Only 38% of the study population remained compliant during the first year of treatment. Over the 4-year follow-up period, the risk of hip fracture among the compliant patients was 70% lower than that among the noncompliant ones (adjusted hazard ratio (HR) 0.30). Among patients with osteoporosis in Taiwan who had experienced a fracture and had started alendronate therapy, compliance with the dosage regimen was suboptimal. It was also found that compliance significantly reduced the risk of secondary hip fracture up to 4 years.

AB - A pharmacoepidemiology study was conducted using the health insurance database in Taiwan to assess compliance with osteoporosis drug regimens and the impact of compliance on the risk for secondary fractures. Patients 50 years of age with vertebral/hip fracture who had been started on alendronate therapy for the first time only after the fracture were included. Compliance was measured using the medication possession ratio (MPR) and was included as a time-dependent covariate in the Cox model to compare the difference between compliant (MPR 80%) and noncompliant patients (MPR 80%) with respect to risk for subsequent hip fractures. Only 38% of the study population remained compliant during the first year of treatment. Over the 4-year follow-up period, the risk of hip fracture among the compliant patients was 70% lower than that among the noncompliant ones (adjusted hazard ratio (HR) 0.30). Among patients with osteoporosis in Taiwan who had experienced a fracture and had started alendronate therapy, compliance with the dosage regimen was suboptimal. It was also found that compliance significantly reduced the risk of secondary hip fracture up to 4 years.

UR - http://www.scopus.com/inward/record.url?scp=79959378065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959378065&partnerID=8YFLogxK

U2 - 10.1038/clpt.2011.62

DO - 10.1038/clpt.2011.62

M3 - Article

C2 - 21525868

AN - SCOPUS:79959378065

VL - 90

SP - 109

EP - 116

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -